Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor used to treat type 2 diabetes mellitus (T2DM), has been shown in studies to have significant cardiovascular benefits that go beyond glucose control[8]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.